Form 4: ResMed Director Sells 2,000 Shares Under 10b5-1 Plan

ResMed Director Peter C. Farrell sold 2,000 shares of common stock for $260.22 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Peter C. Farrell, a Director of ResMed Inc. (RMD), reported a transaction involving the company's common stock.
• On March 4, 2026, Farrell disposed of 2,000 shares of ResMed Common Stock.
• The shares were sold at a price of $260.22 per share.
• This transaction was conducted under a Rule 10b5-1 plan, which was adopted on August 12, 2025.
• Following this transaction, Farrell directly beneficially owns 62,773 shares of ResMed Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine insider transaction under a pre-arranged 10b5-1 plan, which typically does not signal a change in company fundamentals or management's outlook.

Positives

• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-scheduled sale rather than a reaction to recent company news or market conditions.

Negatives

• An insider sale, even if pre-planned, represents a reduction in the director's direct ownership in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider sales executed under Rule 10b5-1 plans are a common practice for executives to manage personal finances and diversify holdings in a compliant manner. Such pre-arranged transactions are generally viewed as less indicative of management's immediate sentiment about the company's prospects compared to unscheduled open market sales.

Stakeholder Impact

• Shareholders: A minor reduction in director ownership, but the pre-planned nature mitigates concerns about immediate company prospects.

Key Dates

Recommendation

The reported transaction is a routine insider sale executed under a Rule 10b5-1 plan, which was adopted several months prior. This type of transaction is typically for personal financial management and does not provide new information that would alter the fundamental investment thesis for ResMed Inc. Therefore, a 'hold' recommendation is appropriate as this filing alone does not suggest a significant change in the company's outlook or valuation.

Keywords

ResMed, RMD, Insider Trading, Form 4, Stock Sale, Director, Peter C. Farrell, 10b5-1 Plan